Praxis Options See Large Bullish Bet Ahead of Two FDA Decisions

A large and newly initiated options trade on Praxis Precision Medicines (NASDAQ: PRAX) indicates a significant bullish bet is being placed ahead of two key U.S. Food and Drug Administration (FDA) drug approval decisions scheduled for this winter.

Sizable Call Spread Targets Upside

Options market data shows a trader executed a 1,000-lot call spread, buying the February 2027 $290 strike calls while simultaneously selling the same number of contracts at the $450 strike. This single structure accounted for 78% of the total call volume in Praxis on the day, according to Investing.com.

The near-zero prior open interest on the $290 calls suggests this is a fresh, directional position rather than an adjustment to an existing one. The trade is structured to profit if Praxis shares, trading around $285.79, rise above the $290 strike price by the February 2027 expiration.

By selling the $450 calls, the trader caps their maximum potential profit but significantly reduces the initial cost of the wager. This strategy points to a conviction that the stock will see a substantial rally, but perhaps not beyond the $450 level, within the next five months.

FDA Catalysts Drive Timing

The trade's February 2027 expiration date appears deliberately chosen to encompass two critical, binary events for the company. Praxis faces two Prescription Drug User Fee Act (PDUFA) dates, which are the FDA's deadlines for a decision on a new drug application.

Ad

The key dates for investors are:

• Dec. 27, 2026: A decision on Relutrigine for treating developmental and epileptic encephalopathies (DEE), a market opportunity the source estimates at over $600 million.
• Jan. 29, 2027: A decision on Ulixacaltamide for essential tremor, representing a potential market of more than $3 billion.

While the $450 strike price is ambitious, it remains below some bullish analyst price targets. Investing.com noted that Raymond James has set a target of $945 and H.C. Wainwright holds a target of $1,245 for the stock.

Market Context and Risks

The options market's pricing reflects the high-stakes nature of the upcoming decisions. While implied volatility is elevated, a collapse in the options skew—a measure of demand for bullish versus bearish contracts—indicates traders are not heavily bidding up the price of protective puts, a mildly constructive signal.

However, significant risks remain. The stock has underperformed recently, down 17.1% over the last month. Investors may also recall that the company's POWER1 trial for a different drug, vormatrigine, missed its primary endpoint in June 2026, a stark reminder that clinical-stage biotechnology investments carry a high degree of risk.